Peptide Drug Conjugates Market 2026 steadily approaching $7.44 billion by 2030

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Peptide Drug Conjugates Market At The End Of The 2026–2030 Forecast Period?

The peptide drug conjugates market size has seen rapid expansion over recent years. It is forecast to increase from $3.64 billion in 2025 to $4.21 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 15.4%. The historical period’s growth can be linked to progress in peptide chemistry, the constraints of traditional chemotherapy, an increase in oncology drug research, the broadening of targeted therapy platforms, and the development of biologics manufacturing.

The peptide drug conjugates market size is anticipated to undergo swift expansion in the upcoming years. It is predicted to attain $7.44 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 15.3%. The projected growth during this period is driven by increasing demand for precision therapies, breakthroughs in linker technologies, the widening scope of cancer indications, augmented investment in peptide drug development, and the proliferation of diagnostic-targeted conjugates. Noteworthy trends for the forecast duration include the intensifying development of targeted peptide conjugates, their growing utilization in oncology therapeutics, a heightened focus on enhancing drug selectivity, the expansion of diagnostic peptide conjugates, and a rise in clinical trials for new conjugates.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24359&type=smp

What Primary Drivers Are Shaping The Development Of The Peptide Drug Conjugates Market?

The increasing need for tailored therapies is projected to fuel the expansion of the peptide drug conjugates market in the upcoming period. These treatments involve medical approaches customized for a person’s specific genetic profile, way of life, and disease traits to optimize results. The surge in personalized treatments stems from progress in genomics, which facilitates the identification of distinct disease indicators, enabling more accurate and impactful therapeutic interventions. They boost peptide drug conjugates by enabling the selection of particular peptides designed to target individual disease biomarkers in patients, resulting in improved precision and efficacy in drug administration. For example, in February 2024, a report from the US-based non-profit organization, the Personalized Medicine Coalition, indicated that the FDA approved 16 new personalized medicines for rare disease patients in 2023, marking a significant increase from the 6 approved in 2022. Consequently, the escalating demand for personalized therapies is expected to accelerate the growth of the peptide drug conjugates market.

What Segment Types Make Up The Peptide Drug Conjugates Market?

The peptide drug conjugates market covered in this report is segmented –

1) By Type: Therapeutic, Diagnostic

2) By Therapy Area: Oncology, Immunology, Infectious Diseases, Other Therapy Areas

3) By Route of Administration: Intravenous, Subcutaneous, Other Routes Of Administration

4) By End User: Hospitals, Clinics, Pharmacies, Other End Users

Subsegments:

1) By Therapeutic: Monoclonal Antibodies (mAbs), Cytotoxic Agents, Immunomodulatory Agents, Targeted Therapies

2) By Diagnostic: Imaging Agents, Biomarker Targeting Agents

Which Market Trends Are Creating New Opportunities In The Peptide Drug Conjugates Market?

Companies at the forefront of the peptide drug conjugates market are prioritizing the development of advanced therapeutic options, such as tumor-selective peptide drug conjugates, to boost treatment precision. Tumor-selective peptide drug conjugates are targeted therapies that employ peptides engineered to specifically bind to cancer cells, enabling the direct delivery of cytotoxic agents to tumors while reducing harm to healthy tissue. For instance, in March 2025, Cybrexa Therapeutics, a US-based oncology biotechnology company, revealed new preclinical data from its alphalex technology. This data showcased the efficacy of Cybrexa’s antigen-agnostic peptide-drug conjugate (PDC) platform in delivering potent microtubule inhibitors straight to tumor cells. This method effectively suppresses tumor growth and induces a durable anti-tumor immune response. These findings highlight the potential of Cybrexa’s technology for enhancing cancer treatment.

Who Are The Key Players Driving Competition In The Peptide Drug Conjugates Market?

Major companies operating in the peptide drug conjugates market are PeptiDream Incorporated, Cybrexa Therapeutics Inc., Oncopeptides Aktiebolag (AB), Soricimed Biopharma Inc., Angiochem Inc., ADC Therapeutics SA, Ambrx Inc., Araris Biotech AG, Adcytherix SA, ProteinQure Incorporated, Esperance Pharmaceuticals Inc., Protagonist Therapeutics Inc., PepGen Corporation, Curium US LLC, AstraZeneca PLC, Novartis AG, Italfarmaco Società per Azioni, BioNTech SE, Theratechnologies Inc., Zealand Pharma A/S

Read the full peptide drug conjugates market report here:

https://www.thebusinessresearchcompany.com/report/peptide-drug-conjugates-global-market-report

How Does The Peptide Drug Conjugates Market Perform Across Major Global Regions?

North America was the largest region in the peptide drug conjugates market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide drug conjugates market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Peptide Drug Conjugates Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24359&type=smp

Browse Through More Reports Similar to the Global Peptide Drug Conjugates Market 2026, By The Business Research Company

Antibody Drug Conjugates Market Report 2026

https://www.thebusinessresearchcompany.com/report/antibody-drug-conjugates-global-market-report

Peptide Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report

Peptide Antibiotics Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-antibiotics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795